We are a long way from psychedelic-assisted therapy being taught in American colleges and Universities. However, that doesn’t mean there...
Cantor Fitzgerald, in reaction to the news, downgraded the stock. The post Seelos Downgraded After Phase 2 Trial Failure appeared first on Green Market...
Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder. The post Cybin Completes Phase 2 Enrollment...
The import to Filament’s Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and...
Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide. The post...
Psilo Scientific, a subsidiary of Filament, will use the leaves to research neuropsychiatric applications. The post Filament Brings Coca Leaves to Canada...
Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations. The post Numinus Closes Bioscience Lab...
Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations. The post Numinus Closes Bioscience Lab...
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced top-line data demonstrating clinically meaningful treatment effects across multiple endpoints and a...
Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated...
